0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Month in Archives of Surgery |

This Month in Archives of Surgery FREE

[+] Author Affiliations

Section Editor: Gerald W. Peskin, MD


Arch Surg. 2003;138(4):353. doi:10.1001/archsurg.138.4.353.
Text Size: A A A
Published online

THEME ISSUE ON THE SURGICAL TREATMENT OF MORBID OBESITY

Morbid obesity is recognized as a serious health problem. The costs associated with obesity are substantial; billions of dollars are spent yearly in the United States on weight reduction, and a goodly portion of that is for treatment of the many complications associated with obesity. In 1991, the second National Institutes of Health Consensus Conference, after reviewing all data, concluded that surgical therapy should be offered to severely obese patients unresponsive to medical therapy. Since that time, the surgical community has settled on the Roux-en-Y gastric bypass, usually performed laparoscopically, and the adjustable gastric banding procedure as the means of accomplishing weight reduction with the fewest complications. We hope that this theme issue will alert you to the principles and pitfalls of bariatric surgery and the newer, and perhaps more physiologic, endocrine approaches to this universal problem.

OVERVIEW OF THE EPIDEMIOLOGY OF OBESITY AND THE EARLY HISTORY OF PROCEDURES TO REMEDY MORBID OBESITY

Kenneth G. MacDonald, Jr, MD, is an authority in the field who has written extensively in this area. He acquaints you with the worldwide problems of morbid obesity, its prevalence, and some of the history of its surgical remedies.

DEVELOPMENT AND FUTURE OF GASTROPLASTIES FOR MORBID OBESITY

This fascinating review of past experience, by the master of bariatric surgeons, Edward E. Mason, MD, PhD, is necessary as a guide to future success with gastroplasties and is presented with attention to the details of each operative approach.

LAPAROSCOPIC ERA OF OPERATIONS FOR MORBID OBESITY

Cottam et al summarize the present and future roles of laparoscopic bariatric surgery.

LAPAROSCOPIC ADJUSTABLE GASTRIC BANDING IN THE TREATMENT OF MORBID OBESITY

This article is by O'Brien and Dixon, who have the most successful series using this technique.

QUALITY OF LIFE: COST AND FUTURE OF BARIATRIC SURGERY

Livingston and Fink describe the criteria and costs of bariatric surgery and emphasize how it improves patients' quality of life.

ROLES FOR GHRELIN IN THE REGULATION OF APPETITE AND BODY WEIGHT

Cummings and Shannon delve into the physiology of appetite and the potential of endocrine approaches to weight reduction. Is this the future?

We have entered the era of genetic analysis as a means of predicting the aggressiveness of tumors. Recently, a scheme for designating breast cancers as favorable or unfavorable based on genetic material from the tumors appeared in the literature. This issue of the ARCHIVES includes a beautiful study of RET proto-oncogene mutations and their relationship to the biological aggressiveness of multiple endocrine neoplasia type 2, adding to the growing body of knowledge relating specific genotypic abnormalities with phenotypic tumor syndromes. Multivariate analysis identified an increased likelihood of advanced medullary thyroid cancer at diagnosis with increasing age and risk group (level 1, 2, or 3 mutations). Current genetic testing can detect 99% of RET mutations. Because of the importance of early intervention in the treatment of medullary thyroid cancer and of screening for pheochromocytoma, identifying mutation patterns in carriers can significantly affect clinical decision making.

The incidental pancreatic cyst periodically plaques us as surgeons. At the recent New England Surgical Society meeting, Castillo et al, drawing on their large series, set forth their concept of the management of such lesions. Because more than half these lesions are malignant or premalignant, occur in older patients, and are smaller than symptomatic cysts, they cannot be dismissed. Using all available diagnostic modalities and a 2-cm cutoff point, they propose an algorithm for managing these lesions.

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.